Amicus Therapeutics
(NASDAQ) FOLD
This security has been delisted. This page is retained for historical reference.
FOLD News
Is Amicus Therapeutics a Buy?
FOLD: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowFOLD Financials
Key Financial Metrics (TTM)
Gross Margin
88%
Operating Margin
5%
Net Income Margin
-4%
Return on Equity
-12%
Return on Capital
5%
Return on Assets
-3%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$553.82M
Operating Income
$34.49M
EBITDA
$53.81M
Operating Cash Flow
$33.15M
Capital Expenditure
$3.30M
Free Cash Flow
$29.85M
Cash & ST Invst.
$293.54M
Total Debt
$483.32M
Amicus Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$185.21M
+23.7%
Gross Profit
$156.77M
+16.2%
Gross Margin
84.64%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
499
N/A
Net Income
$1.69M
-88.5%
EBITDA
$16.47M
-24.9%
Quarterly Fundamentals
Net Cash
$189.79M
+2.0%
Accounts Receivable
$115.31M
+14.1%
Inventory
$228.82M
+92.6%
Long Term Debt
$474.58M
+9.1%
Short Term Debt
$8.74M
+3.4%
Return on Assets
-2.85%
N/A
Return on Invested Capital
4.60%
N/A
Free Cash Flow
$15.95M
+479.5%
Operating Cash Flow
$16.25M
+515.0%